DALLAS, March 29, 2015 /PRNewswire-iReach/ -- The report
"CountryFocus: Healthcare, Regulatory and Reimbursement
Landscape – Japan" is an essential source of information on and
analysis of the healthcare, regulatory and reimbursement landscape
in Japan. It identifies the key
trends in the country's healthcare market and provides insights
into its demographic, regulatory, and reimbursement landscape and
healthcare infrastructure. Most importantly, the report provides
valuable insights into the trends and segmentation of the
pharmaceutical and medical device markets.
Photo - http://photos.prnewswire.com/prnh/20150327/194921
Japan's pharmaceutical
market value is set to grow at a tepid Compound Annual Growth
Rate (CAGR) of 1.3% from $72.8
billion in 2013 to reach $79.8
billion by 2020, driven by new product launches and the
healthcare burden of the country's aging population, according to
research and consulting firm GlobalData. However, the company's
latest report states that the Japanese government's promotion of
generic drugs, its biennial pricing review system and the
depreciation of the yen against the dollar will be limiting factors
in what is the second largest mature pharmaceutical market in the
world by value.
The market was valued at $64.2
billion in 2008 and peaked at $88
billion in 2011, before a slight dip to $87.2 billion in 2012. A substantial drop in 2013
saw its value decrease by over $14
billion. In 2013, Japan's
population was approximately 127.2 million, having declined at a
negative CAGR of 0.02% from 2008. Its public healthcare expenditure
accounted for 82.8% of total healthcare expenditure, and the
government spent approximately $14
billion on pharmaceutical R&D. Order a Purchase copy
of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=329874 .
(This is a premium report priced at US$3995 for a single user License.)
Deregulation measures introduced in April
2005 have had an impact on overall market performance and
more efficient drug reviews have facilitated the entry of new
products. The approval process has now caught up with that outside
of Japan, as highlighted by two
approvals for Bristol-Myers Squibb, the Daklinza (daclatasvir) and
Sunvepra (asunaprevir) dual regimen for hepatitis C, and Opdivo
(nivolumab) for melanoma, prior to their approval by the US Food
and Drug Administration. Aside from wider economic factors, such as
currency exchange rates, GlobalData states that increased use of
generic drugs will be a key contributor to the forthcoming period
of slow growth to 2020.
Scope
The report provides information on the healthcare, regulatory,
and reimbursement landscape in Japan and includes –
- An overview of the pharmaceutical and medical device markets,
including market size, segmentation, and key drivers and
barriers
- Profiles and SWOT analysis of the major players in the
pharmaceutical market (Takeda, Otsuka, Pfizer, Astellas and Daiichi
Sankyo) and medical device market (Hoya, Siemens Healthcare,
Abbott, Medtronic and F. Hoffmann-La Roche)
- A review of the reimbursement and regulatory landscape, with
analysis covering details of the country's healthcare reimbursement
process, regulatory agencies and the approval processes for new
drugs and medical devices
- Detailed analysis of the political and economic environment,
covering economic indicators, demographics, healthcare
infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth
in the healthcare market
Reasons to buy
This report will enhance your decision-making capability by
allowing you to –
- Develop business strategies by understanding the trends shaping
and driving Japan's healthcare
market
- Drive revenue by understanding the key trends, reimbursement
and regulatory policies, pharmaceutical market segments, and
companies likely to affect Japan's
healthcare market
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and analyzing the
performance of various competitors
- Organize your sales and marketing efforts by identifying the
market categories and segments that present the best opportunities
for consolidation, investment, and strategic partnerships
- Identify, understand, and capitalize on the opportunities and
challenges in Japan's healthcare
market
Major Points in Table of
Contents
3 Overview of the Pharmaceutical and Medical Device
Markets
3.1 Pharmaceutical Market
3.1.1 Market Overview
3.1.2 Pharmaceutical Imports and Exports
3.1.3 Supply Channels
3.1.4 Market Segments
3.1.5 Major Therapeutic Areas
3.1.6 Major Players
3.2 Medical Device Market
3.2.1 Market Overview
3.2.2 Overview of Top-Five Segments
3.2.3 Diagnostics Market
3.2.4 Major Players
3.3 Market Drivers and Barriers
3.3.1 Drivers
3.3.2 Barriers
4 Market Access
4.1 Reimbursement and Payer Landscape
4.1.1 Overview of the Healthcare System
4.1.2 Reimbursement Process
4.1.3 Overview of Insurance Providers
4.1.4 Patients' Share of Healthcare Spending
4.1.5 Prescription Drug Price Trend
4.1.6 Pricing Policies
4.2 Regulatory Landscape
4.2.1 Overview
4.2.2 Regulatory Agencies
4.2.3 Market Authorization Procedure for Pharmaceutical
Products
4.2.4 New Device Approval Process
4.2.5 Licensing Process for Pharmaceutical and Medical Device
Manufacturing
4.2.6 Licensing for Pharmaceutical Exports and Imports
4.2.7 Intellectual Property Rights
4.2.8 Clinical Trial Regulations
4.2.9 Pharmaceutical Advertising Regulations
4.2.10 Pharmacy Regulations
4.2.11 Labeling and Packaging
Regulations
5 Country Analysis
5.1 Political Environment
5.1.1 Political Structure
5.1.2 Analysis of Current Political Environment
5.1.3 Healthcare Policy Initiatives
5.2 Economic Landscape
5.3 Economic Indicators
5.3.1 Gross Domestic Product
5.3.2 Gross National Income
5.3.3 Inflation
5.3.4 Currency Exchange Rate
5.3.5 Foreign Direct Investment
5.3.6 Foreign Exchange Reserves
5.3.7 Trade Balance
5.3.8 General Government Structural Balance
5.3.9 General Government Gross Debt
5.3.10 Major Industries
5.4 Demographics
5.4.1 Population
5.4.2 Education and Literacy
5.4.3 Employment
5.4.4 Disease Burden
5.5 Healthcare Infrastructure
5.5.1 Healthcare Facilities
5.5.2 Healthcare Parameters
5.5.3 Environmental Health
5.5.4 Healthcare Personnel
5.6 Healthcare Expenditure
5.6.1 Overview
5.6.2 Major Components of Healthcare Spending
5.6.3 Share of Public and Private Sector
5.6.4 Pharmaceutical and Healthcare R&D Expenditure
5.7 Trade Associations
5.7.1 Japan Pharmaceutical Manufacturers Association
5.7.2 Federation of Pharmaceutical Manufacturers' Associations
5.7.3 Japan Pharmaceutical Traders Association
5.7.4 Japan Pharmaceutical Equipment and Machinery Association
5.8 Trade Fairs
6 Opportunities and Challenges
6.1 Opportunities
6.2 Challenges
Explore more reports on Solar Photovoltaic (PV) at
http://www.rnrmarketresearch.com/reports/energy-power/energy/photovoltaics-pv/solar-photovoltaic-pv
.
About Us:
RnRMarketResearch.com is a database of selected syndicated
market reports for global and China industries including but not limited to
life sciences, information technology & telecommunications,
consumer goods, food and beverages, energy and power, automotive
and transportation, manufacturing and construction, materials and
chemicals, public sector as well as business and financial
services. We provide 24/7 online and offline support to our
customers.
Media Contact: Ritesh Tiwari, RnR Market Research,
+1888391544, sales@rnrmarketresearch.com
News distributed by PR Newswire iReach:
https://ireach.prnewswire.com
SOURCE RnRMarketResearch